Genzyme Study of Myozyme® for Late-Onset Pompe Patients

CAMBRIDGE, Mass. – Genzyme Corp. (Nasdaq: GENZ) announced today that its Late Onset Treatment Study (LOTS) of Myozyme® (alglucosidase alfaA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More) met its co-primary efficacy endpoints.  The study was undertaken to evaluate the safety and efficacy of MyozymeA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More in juvenile and adult patients with Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More.  MyozymeA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of ... More was first approved in 2006, and the product is now registered in 36 countries.